China actively optimizes COVID-19 response measures to better prepare for challenges
BEIJING, Dec. 26, 2022 /PRNewswire/ -- As multiple regions in China have seen surging COVID-19 infections, local governments are taking swift and precise measures to prevent severe cases, protect people's health, and build a barrier against the epidemic. These measures include providing timely medical treatment, meeting medicine needs, improving health services for the elderly and other key groups, promoting...
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company’s Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 26, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19 vaccine ReCOV in the Philippines. This clinical study aims to...
Pulnovo Medical will be attending JPM Healthcare Conference 2023
SHANGHAI, Dec. 24, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovative platform, will be attending the upcoming 41st J.P. Morgan Healthcare Conference 2023 to discuss the latest trends in innovative technologies and development strategies in the medical device sector with global peers. This will be the first time that Pulnovo will be participating in the J.P....
AAHRPP Accredits Three More Research Organizations, Including First Hospital in Japan
Twelve earn accreditation in 2022, returning to pre-COVID-19 levels WASHINGTON, Dec. 23, 2022 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs has accredited three more research organizations, including the first hospital in Japan, the flagship university of New Jersey and a consortium of over 150 U.S. colleges and...
Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals
Winlevi® is a first-in-class topical drug for the treatment of acne approved by U.S. FDA in August 2020. It will reinforce our Proprietary Brand segment's dermatological franchise. SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare...
PVmed Raises US $14 Million Series A Funding from Cherami, Philips, JHF, COCOCAPITAL, and Strategy Capital
Will Support Rapid Expansion of PVmed's AI Cancer Treatment Product Portfolio GUANGZHOU, China, Dec. 23, 2022 /PRNewswire/ -- Perception Vision Medical Technologies Co., Ltd. (PVmed), a global artificial intelligence (AI) cancer treatment company, headquartered in Guangzhou, China, has secured US $14 million (RM 100 million) in Series A funding from investors including Cherami Investment Group, Philips, JHF Investment,...
JUNIPER BIOLOGICS WINS M&A AWARD 2022 BY ACQUISITION INTERNATIONAL
Best Cell & Gene Therapy Acquisition 2022: Juniper Biologics/Kolon Life Science SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd, a science-led healthcare company focused on commercialising novel therapies, was awarded Acquisition International's M&A Award 2022 for the category of Best Cell & Gene Therapy Acquisition 2022. Acquisition international hosted the M&A awards for the sixth year,...
Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma
SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO® (selinexor) to the Pharmaceutical Administration...
Ubitus and Smart Surgery enable doctors to practice robotic surgery with VR streaming
TOKYO, Dec. 22, 2022 /PRNewswire/ -- Ubitus K.K. (hereinafter Ubitus), a world-leading metaverse solution provider, supports Smart Surgery Technology to roll out its VR driven surgery simulation application – Sim Surgery. Smart Surgery Technology successfully demonstrated this innovative product at Medical Taiwan Exhibition from the 1st to the 4th of December, 2022. ...
FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
Exploring Xanamem® and the "cortisol hypothesis" for more than 6 million Americans suffering from Alzheimer's Disease SYDNEY, Dec. 22, 2022 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2b, placebo-controlled clinical trial of...
